There has been an increase in R&D spending but a decline in research productivity, potentially leaving drug developers with insufficient pipelines. Mergers and acquisitions have aimed to strengthen pipelines and gain scale but larger companies now focus on blockbuster drugs. Licensing has become a major source of new products for large pharmaceutical companies and deals are occurring earlier in development stages.
This document discusses factors related to switching medications from prescription to over-the-counter status. It begins by defining Rx-to-OTC switching as transferring FDA-approved prescription medications to non-prescription, over-the-counter status. The document then covers stakeholders impacted by switching, the switching process and principles, factors contributing to successful switches, considerations for switches, and strategies for building brand equity during and after a switch from prescription to over-the-counter status.
New Product Planning in the Pharmaceutical IndustryAnthony Russell
?
Lecture presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on June 14, 2020 at USC via Zoom. The lectures gives an overview of what new product planning is in the pharmaceutical industry, what tools are used during new product evaluations, and the key elements of a new product business case. The lecture includes a couple of case studies to be worked on by the class.
The document provides an overview of the global and Indian pharmaceutical industries and pharmaceutical marketing. It discusses how pharmaceutical companies research and develop new drugs, the large market size and top companies globally and in India, India's role as a major exporter of generic drugs, and common marketing strategies used in India's prescription-driven branded generic market, which involve establishing relationships with doctors who are the key decision-makers through regular visits and promotion by marketing representatives.
ANALYZING (BUSINESS DEVELOPMENT) IN PHARMACEUTICAL COMPANIESPharm Net
?
This document discusses strategic challenges and opportunities for pharmaceutical business development functions. It addresses factors that determine the future value of deals, how to profile ideal opportunities, techniques for evaluating opportunities, and critical success factors for negotiating deals and managing strategic alliances. The document provides an overview of various topics related to business development strategy and dealmaking in the pharmaceutical industry.
The document summarizes research into marketing practices of pharmaceutical companies through case studies and interviews. Case studies of Claritin and Lipitor found differences in packaging and advertising between US/Canada and Europe. Interviews found that pharmaceutical representatives meet with doctors and pharmacists for 10-30 minutes to provide information, but independent assessment is still needed. While representatives have useful roles, direct-to-consumer drug advertising is seen as generally inappropriate.
Ersnt & Young Pharma 3.0 Business Model Zaki Sellam
?
Pharma companies are transforming their business models from Pharma 1.0 focused on blockbuster drugs, to Pharma 2.0 with diversified drug portfolios, and now to Pharma 3.0 centered around delivering healthy outcomes. This transformation is being driven by factors like healthcare reform, consumerism, and the need to prove value. Pharma 3.0 requires non-traditional collaborations across different industries in the healthy outcomes ecosystem, including providers, IT companies, social media platforms, and more, to achieve the goal of improving patient health.
The document discusses various aspects of the pharmaceutical industry. It describes the different departments in a pharmaceutical company including IT, finance, human resources, supply chain, marketing, and others. It also discusses the manufacturing process which involves obtaining raw materials, testing drugs in laboratory phases, gaining regulatory approval, and packaging medications for distribution. The industry plays an important role in India's economy and healthcare sector.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures and sells drugs globally and is the largest pharmaceutical company in India. To address productivity issues due to large number of employees, Sun Pharma implemented an app developed by Affle that allowed centralized travel booking. This improved resource planning and coordination across geographies. Sun Pharma's incentive policy includes competitive fixed salaries, variable pay based on performance, share-based incentives, and non-monetary benefits like insurance and accommodation to retain key employees.
intertnational council for harmonization The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects Details of the ICH guidelines for pharmaceutical quality from Q1 to Q12 including stability analysis, evaluation of impurities and quality risk management. ICH (Full form = International Conference on Harmonisation) is a committee that provides the pharmaceutical guidelines for industries.
How Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio Medixambitbiomedix12
?
If you are looking to many types of Marketing Strategies in Pharma Sector then Ambit Bio Medix is one of best top 10 pharma franchise companies at the best price. Here are the Many Types of Marketing Strategies in Pharma Sector.
The document discusses the Indian pharmaceutical industry. It provides an overview of major players, the Indian and global scenarios, future outlook, and areas for boosting competitiveness. The industry has grown significantly over time and India is now a top producer and exporter of generic drugs globally. The outlook remains positive with the market expected to reach $74 billion by 2020 and become one of the top ten markets worldwide. However, further investment in R&D and addressing regulatory issues can help strengthen the industry.
Analysis of stock market after Covid-19 By Anshika SinghAnshikaSingh141
?
The rapid spread of the unprecedented COVID- 19 pandemic has put the world in jeopardy and changed the global outlook unexpectedly.
As many countries adopt strict quarantine policies to fight with the unseen pandemic, their economic activities are suddenly shut down
Most of the developed and developing countries’ financial markets were drastically affected by this pandemic. Here we would like to observe and analyse the impact of COVID-19 on certain sectors of the indian economy in the stock market
Pharmaceutical Marketing - Whats in store for patients?brandsynapse
?
This document discusses trends in pharmaceutical marketing and advertising spending from 1996 to 2010. Key points include:
- U.S. pharmaceutical ad spending peaked at $5.4 billion in 2006 but has declined each year since to $4.3 billion in 2010 due to fewer blockbuster drugs, a smaller new drug pipeline, and cost cutting.
- The top spender in 2010 was Pfizer at $967.5 million, though its drug Lipitor will go off patent in 2011. Other top drugs like Plavix and Singulair will also lose patent protection.
- As mainstream breakthrough drugs become fewer, pharmaceutical marketers will need to create more value for newer drugs with smaller benefits and target niche patient
Visdios is a specialist in key opinion leader management, development, implement process and also manage all kind of KOL solutions across your company. We engage with our valuable customers to get a real understanding of their business requirements.
http://visdios.com/kol-management-india/
The document discusses key opinion leader (KOL) identification and selection for pharmaceutical companies. It outlines regulatory guidance requiring transparency in KOL relationships and selection criteria based on medical expertise. The document proposes that citation analysis is an effective method for determining a scientist's influence and peer esteem, as shown by Thomson Reuters' success in predicting Nobel Prize winners based primarily on citations. It provides methods for identifying KOLs based on a company's business needs, such as publication count for new markets or citation analysis for established markets. The document recommends aligning KOLs with development stages, using both established leaders and rising stars.
The document discusses generics medicines in India. It notes that the Indian pharmaceutical market is predominantly a branded generics market, with generics accounting for around 90% of total sales. The government of India is focused on boosting generics growth within India and for exports. However, the generics industry faces challenges from regulatory/licensing issues. The conference aims to address these challenges and find solutions to promote the generics industry in India.
The document provides an overview of the pharmaceutical market in Pakistan. It includes key facts and figures on the size and growth of the Pakistani pharmaceutical market, which reached PKR 343 billion in 2017. It also details the country's healthcare system structure, leading therapeutic classes, and import/export partners. The top 100 pharmaceutical companies account for over 95% of the market by both value and units. The market is growing at a projected rate of 11.42% annually.
Drug market structure (Pharma in Indian Scenario)hemant vyas
?
This document provides an overview of the pharmaceutical industry in India. It discusses the growth and structure of the industry, both globally and within India. It notes that while India is a major producer of generic drugs, its research and development spending and capabilities remain relatively low. The industry in India is characterized by high profitability and concentration among the largest companies.
The document summarizes research into marketing practices of pharmaceutical companies through case studies and interviews. Case studies of Claritin and Lipitor found differences in packaging and advertising between US/Canada and Europe. Interviews found that pharmaceutical representatives meet with doctors and pharmacists for 10-30 minutes to provide information, but independent assessment is still needed. While representatives have useful roles, direct-to-consumer drug advertising is seen as generally inappropriate.
Ersnt & Young Pharma 3.0 Business Model Zaki Sellam
?
Pharma companies are transforming their business models from Pharma 1.0 focused on blockbuster drugs, to Pharma 2.0 with diversified drug portfolios, and now to Pharma 3.0 centered around delivering healthy outcomes. This transformation is being driven by factors like healthcare reform, consumerism, and the need to prove value. Pharma 3.0 requires non-traditional collaborations across different industries in the healthy outcomes ecosystem, including providers, IT companies, social media platforms, and more, to achieve the goal of improving patient health.
The document discusses various aspects of the pharmaceutical industry. It describes the different departments in a pharmaceutical company including IT, finance, human resources, supply chain, marketing, and others. It also discusses the manufacturing process which involves obtaining raw materials, testing drugs in laboratory phases, gaining regulatory approval, and packaging medications for distribution. The industry plays an important role in India's economy and healthcare sector.
Sun Pharmaceutical Industries is an Indian pharmaceutical company headquartered in Mumbai. It manufactures and sells drugs globally and is the largest pharmaceutical company in India. To address productivity issues due to large number of employees, Sun Pharma implemented an app developed by Affle that allowed centralized travel booking. This improved resource planning and coordination across geographies. Sun Pharma's incentive policy includes competitive fixed salaries, variable pay based on performance, share-based incentives, and non-monetary benefits like insurance and accommodation to retain key employees.
intertnational council for harmonization The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects Details of the ICH guidelines for pharmaceutical quality from Q1 to Q12 including stability analysis, evaluation of impurities and quality risk management. ICH (Full form = International Conference on Harmonisation) is a committee that provides the pharmaceutical guidelines for industries.
How Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio Medixambitbiomedix12
?
If you are looking to many types of Marketing Strategies in Pharma Sector then Ambit Bio Medix is one of best top 10 pharma franchise companies at the best price. Here are the Many Types of Marketing Strategies in Pharma Sector.
The document discusses the Indian pharmaceutical industry. It provides an overview of major players, the Indian and global scenarios, future outlook, and areas for boosting competitiveness. The industry has grown significantly over time and India is now a top producer and exporter of generic drugs globally. The outlook remains positive with the market expected to reach $74 billion by 2020 and become one of the top ten markets worldwide. However, further investment in R&D and addressing regulatory issues can help strengthen the industry.
Analysis of stock market after Covid-19 By Anshika SinghAnshikaSingh141
?
The rapid spread of the unprecedented COVID- 19 pandemic has put the world in jeopardy and changed the global outlook unexpectedly.
As many countries adopt strict quarantine policies to fight with the unseen pandemic, their economic activities are suddenly shut down
Most of the developed and developing countries’ financial markets were drastically affected by this pandemic. Here we would like to observe and analyse the impact of COVID-19 on certain sectors of the indian economy in the stock market
Pharmaceutical Marketing - Whats in store for patients?brandsynapse
?
This document discusses trends in pharmaceutical marketing and advertising spending from 1996 to 2010. Key points include:
- U.S. pharmaceutical ad spending peaked at $5.4 billion in 2006 but has declined each year since to $4.3 billion in 2010 due to fewer blockbuster drugs, a smaller new drug pipeline, and cost cutting.
- The top spender in 2010 was Pfizer at $967.5 million, though its drug Lipitor will go off patent in 2011. Other top drugs like Plavix and Singulair will also lose patent protection.
- As mainstream breakthrough drugs become fewer, pharmaceutical marketers will need to create more value for newer drugs with smaller benefits and target niche patient
Visdios is a specialist in key opinion leader management, development, implement process and also manage all kind of KOL solutions across your company. We engage with our valuable customers to get a real understanding of their business requirements.
http://visdios.com/kol-management-india/
The document discusses key opinion leader (KOL) identification and selection for pharmaceutical companies. It outlines regulatory guidance requiring transparency in KOL relationships and selection criteria based on medical expertise. The document proposes that citation analysis is an effective method for determining a scientist's influence and peer esteem, as shown by Thomson Reuters' success in predicting Nobel Prize winners based primarily on citations. It provides methods for identifying KOLs based on a company's business needs, such as publication count for new markets or citation analysis for established markets. The document recommends aligning KOLs with development stages, using both established leaders and rising stars.
The document discusses generics medicines in India. It notes that the Indian pharmaceutical market is predominantly a branded generics market, with generics accounting for around 90% of total sales. The government of India is focused on boosting generics growth within India and for exports. However, the generics industry faces challenges from regulatory/licensing issues. The conference aims to address these challenges and find solutions to promote the generics industry in India.
The document provides an overview of the pharmaceutical market in Pakistan. It includes key facts and figures on the size and growth of the Pakistani pharmaceutical market, which reached PKR 343 billion in 2017. It also details the country's healthcare system structure, leading therapeutic classes, and import/export partners. The top 100 pharmaceutical companies account for over 95% of the market by both value and units. The market is growing at a projected rate of 11.42% annually.
Drug market structure (Pharma in Indian Scenario)hemant vyas
?
This document provides an overview of the pharmaceutical industry in India. It discusses the growth and structure of the industry, both globally and within India. It notes that while India is a major producer of generic drugs, its research and development spending and capabilities remain relatively low. The industry in India is characterized by high profitability and concentration among the largest companies.